These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

449 related articles for article (PubMed ID: 33334002)

  • 1. Pharmacological Approaches to Controlling Cardiometabolic Risk in Women with PCOS.
    Cignarella A; Mioni R; Sabbadin C; Dassie F; Parolin M; Vettor R; Barbot M; Scaroni C
    Int J Mol Sci; 2020 Dec; 21(24):. PubMed ID: 33334002
    [TBL] [Abstract][Full Text] [Related]  

  • 2. AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS, AMERICAN COLLEGE OF ENDOCRINOLOGY, AND ANDROGEN EXCESS AND PCOS SOCIETY DISEASE STATE CLINICAL REVIEW: GUIDE TO THE BEST PRACTICES IN THE EVALUATION AND TREATMENT OF POLYCYSTIC OVARY SYNDROME--PART 1.
    Goodman NF; Cobin RH; Futterweit W; Glueck JS; Legro RS; Carmina E; ; ;
    Endocr Pract; 2015 Nov; 21(11):1291-300. PubMed ID: 26509855
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The cardiometabolic effect of current management of polycystic ovary syndrome: strategies of prevention and treatment.
    Baldani DP; Skrgatic L; Ougouag R; Kasum M
    Gynecol Endocrinol; 2018 Feb; 34(2):87-91. PubMed ID: 28944709
    [TBL] [Abstract][Full Text] [Related]  

  • 4. AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS, AMERICAN COLLEGE OF ENDOCRINOLOGY, AND ANDROGEN EXCESS AND PCOS SOCIETY DISEASE STATE CLINICAL REVIEW: GUIDE TO THE BEST PRACTICES IN THE EVALUATION AND TREATMENT OF POLYCYSTIC OVARY SYNDROME - PART 2.
    Goodman NF; Cobin RH; Futterweit W; Glueck JS; Legro RS; Carmina E; ; ;
    Endocr Pract; 2015 Dec; 21(12):1415-26. PubMed ID: 26642102
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The prevalence, phenotype and cardiometabolic risk of polycystic ovary syndrome in treatment-naïve transgender people assigned female at birth.
    Oğuz SH; Boyraz BS; Ertürk B; Yıldız BO
    Endocrine; 2024 Apr; 84(1):287-292. PubMed ID: 38141060
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Androgen levels in women with various forms of ovarian dysfunction: associations with cardiometabolic features.
    Daan NM; Jaspers L; Koster MP; Broekmans FJ; de Rijke YB; Franco OH; Laven JS; Kavousi M; Fauser BC
    Hum Reprod; 2015 Oct; 30(10):2376-86. PubMed ID: 26269538
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Left ventricular myocardial mass index and its correlates as an early marker of cardiovascular risk among nonobese normotensive Indian women with polycystic ovary syndrome: lessons from a cross-sectional study.
    Rashid A; Masood A; Wani IA; Hafeez I; Parvez T; Zagar MA; Ganie MA
    Fertil Steril; 2020 Jun; 113(6):1299-1307.e2. PubMed ID: 32482259
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Management of cardiometabolic complications in polycystic ovary syndrome: Unmet needs.
    Yanes Cardozo LL; Romero DG
    FASEB J; 2021 Nov; 35(11):e21945. PubMed ID: 34606638
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cardiometabolic biomarkers in women with polycystic ovary syndrome.
    van der Ham K; Louwers YV; Laven JSE
    Fertil Steril; 2022 May; 117(5):887-896. PubMed ID: 35512973
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Statin therapy worsens insulin sensitivity in women with polycystic ovary syndrome (PCOS): a prospective, randomized, double-blind, placebo-controlled study.
    Puurunen J; Piltonen T; Puukka K; Ruokonen A; Savolainen MJ; Bloigu R; Morin-Papunen L; Tapanainen JS
    J Clin Endocrinol Metab; 2013 Dec; 98(12):4798-807. PubMed ID: 24152688
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of long-term administration of an oral contraceptive containing ethinylestradiol and cyproterone acetate on lipid metabolism in women with polycystic ovary syndrome.
    Falsetti L; Pasinetti E
    Acta Obstet Gynecol Scand; 1995 Jan; 74(1):56-60. PubMed ID: 7856434
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Influence of adrenal hyperandrogenism on the clinical and metabolic phenotype of women with polycystic ovary syndrome.
    Alpañés M; Luque-Ramírez M; Martínez-García MÁ; Fernández-Durán E; Álvarez-Blasco F; Escobar-Morreale HF
    Fertil Steril; 2015 Mar; 103(3):795-801.e2. PubMed ID: 25585504
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Elevated fasting insulin is associated with cardiovascular and metabolic risk in women with polycystic ovary syndrome.
    Rasool SUA; Ashraf S; Nabi M; Rashid F; Fazili KM; Amin S
    Diabetes Metab Syndr; 2019; 13(3):2098-2105. PubMed ID: 31235143
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Effect of 6-month treatment with oral antiandrogen alone and in combination with insulin sensitizers on body composition, hormonal and metabolic parameters in women with polycystic ovary syndrome (PCOS) in order to determine therapeutic strategy].
    Orbetsova M; Kamenov Z; Kolarov G; Zakharieva S; Khristov V; Atanasova I; Shigarminova R; Milcheva B; Genchev G
    Akush Ginekol (Sofiia); 2006; 45(7):16-28. PubMed ID: 17489164
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of Lifestyle Intervention on Cardiometabolic Risk Factors in Overweight and Obese Women with Polycystic Ovary Syndrome: A Systematic Review and Meta-Analysis.
    Khatlani K; Njike V; Costales VC
    Metab Syndr Relat Disord; 2019 Dec; 17(10):473-485. PubMed ID: 31513475
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Assessment of cardiovascular risk and prevention of cardiovascular disease in women with the polycystic ovary syndrome: a consensus statement by the Androgen Excess and Polycystic Ovary Syndrome (AE-PCOS) Society.
    Wild RA; Carmina E; Diamanti-Kandarakis E; Dokras A; Escobar-Morreale HF; Futterweit W; Lobo R; Norman RJ; Talbott E; Dumesic DA
    J Clin Endocrinol Metab; 2010 May; 95(5):2038-49. PubMed ID: 20375205
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of ethinyl-estradiol plus cyproterone acetate versus metformin effects on classic metabolic cardiovascular risk factors in women with the polycystic ovary syndrome.
    Luque-Ramírez M; Alvarez-Blasco F; Botella-Carretero JI; Martínez-Bermejo E; Lasunción MA; Escobar-Morreale HF
    J Clin Endocrinol Metab; 2007 Jul; 92(7):2453-61. PubMed ID: 17426085
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comprehensive Evaluation of Type 2 Diabetes and Cardiovascular Disease Risk Profiles in Reproductive-Age Women with Polycystic Ovary Syndrome: A Large Canadian Cohort.
    Kazemi M; Pierson RA; Lujan ME; Chilibeck PD; McBreairty LE; Gordon JJ; Serrao SB; Zello GA; Chizen DR
    J Obstet Gynaecol Can; 2019 Oct; 41(10):1453-1460. PubMed ID: 30712903
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ethinylestradiol-drospirenone, flutamide-metformin, or both for adolescents and women with hyperinsulinemic hyperandrogenism: opposite effects on adipocytokines and body adiposity.
    Ibáñez L; de Zegher F
    J Clin Endocrinol Metab; 2004 Apr; 89(4):1592-7. PubMed ID: 15070917
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oral contraceptives versus physical exercise on cardiovascular and metabolic risk factors in women with polycystic ovary syndrome: a randomized controlled trial.
    Orio F; Muscogiuri G; Giallauria F; Savastano S; Bottiglieri P; Tafuri D; Predotti P; Colarieti G; Colao A; Palomba S
    Clin Endocrinol (Oxf); 2016 Nov; 85(5):764-771. PubMed ID: 27219465
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.